Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New device aims to strengthen neck fusion surgery

NCT ID NCT04229017

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a device called PCSS used alongside standard neck fusion surgery to treat degenerative disc disease in the neck. About 236 adults aged 18-80 who need surgery on three neck levels will be enrolled. The goal is to see if the device helps bones fuse better and safely compared to surgery without it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 236 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2020

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-80 years (Skeletally Mature) 2. Indicated for ACDF treatment of degenerative disc disease (DDD) between and including C3-C7 at 3 contiguous levels 3. NDI Score of ≥15/50 4. Unresponsive to non-operative, conservative treatment (rest, heat, electrotherapy, physical therapy, chiropractic care and/or analgesics) 5. Reported to be medically cleared for surgery 6. Physically and mentally able and willing to comply with the Protocol, including the ability to read and complete required forms and willing and able to adhere to the scheduled follow-up visits and requirements of the Protocol. 7. Written informed consent provided by subject Exclusion Criteria: 1. Body Mass Index (BMI) greater than 40 kg/m2 2. Active systemic infection or infection at the operative site 3. History of or anticipated treatment for active systemic infection, including HIV or Hepatitis C 4. Previous trauma to the C3 to C7 levels resulting in significant bony or disco- ligamentous cervical spine injury that may prevent device placements 5. A prior spine surgery or pseudoarthrosis at the operative levels 6. Axial neck pain in the absence of other symptoms of radiculopathy or myeloradiculopathy justifying the need for surgical intervention 7. Symptomatic DDD or significant cervical spondylosis at more than three levels 8. Diagnosis of spondylolisthesis, grade \>2 9. Overt (Segmental) instability measured as a movement on dynamic flex/ext x-rays \>3.5 mm 10. Congenital bony and/or spinal cord abnormalities that affect spinal stability 11. Diagnosis of Paget's disease, osteomalacia or any other metabolic bone disease other than osteoporosis 12. Osteoporosis, defined as either the SCORE or MORES ≥ 6 and a DEXA bone density measured T-score of ≤ -2.5 13. Active malignancy or a history of any invasive malignancy (except non-melanoma skin cancer), unless treated with curative intent and without clinical signs or symptoms of the malignancy for at least five years 14. Has an uncontrolled seizure disorder 15. Use of epidural steroids within 14 days prior to surgery 16. A concomitant condition requiring daily, high-dose oral and/or inhaled steroids 17. Known allergy to titanium (Ti). 18. Fixed or permanent neurologic deficit related to the target treatment levels that cannot be improved with surgical decompression 19. Has, in the Investigator's opinion, any disease or condition that would preclude accurate clinical evaluation (e.g. neuromuscular disorders). 20. Is pregnant or nursing at time of screening, or with plans to become pregnant within the next three years. 21. A current or recent history (≤ 1 year prior to screening) of substance abuse (alcoholism and/or narcotic addiction) that required treatment. 22. Long term use (\>6 months) of opioids (max. daily amount=120 mg morphine equivalents). 23. A mental illness or belongs to a vulnerable population, as determined by the investigator (e.g., prisoner or developmentally disabled), that would compromise ability to provide informed consent or compliance with follow-up requirements. 24. Any other condition or anatomy (e.g. fused facet) that makes posterior fusion treatment infeasible 25. Use of any other investigational drug or medical device within the last 30 days prior to surgery. 26. A pending personal litigation relating to spinal injury (worker's compensation is not exclusionary). 27. Anticipated or potential relocation greater than 50 miles that may interfere with completion of follow-up examinations.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Degenerative disc disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Atlantic Neurosurgical & Spine Specialists

    Wilmington, North Carolina, 28401, United States

  • Barrow Neurological Institute

    Phoenix, Arizona, 85013, United States

  • Baylor College of Medicine

    Houston, Texas, 77030, United States

  • Beaumont Health

    Royal Oak, Michigan, 48073, United States

  • Bone and Joint Clinic of Baton Rouge

    Baton Rouge, Louisiana, 70808, United States

  • Inspira Health Network

    Vineland, New Jersey, 08361, United States

  • LSU Health

    New Orleans, Louisiana, 70112, United States

  • LifeBridge Health - Sinai Hospital of Baltimore

    Baltimore, Maryland, 21215, United States

  • OrthoNorCal

    Los Gatos, California, 95032, United States

  • Pinehurst Surgical Clinic

    Pinehurst, North Carolina, 28374, United States

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States

  • Scripps

    Encinitas, California, 92024, United States

  • Spine Colorado

    Durango, Colorado, 81301, United States

  • Spine Institute of Louisiana

    Shreveport, Louisiana, 71101, United States

  • The Orthopaedic Institute

    Paducah, Kentucky, 42001, United States

  • The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, 27599, United States

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.